Prevent-AD

Prevent-AD. The Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (Prevent-AD) is a landmark longitudinal cohort study and clinical trial platform based in Montreal, Canada. Initiated in 2011, it focuses on identifying the earliest biological changes in individuals at high genetic risk for developing Alzheimer's disease long before clinical symptoms appear. The study is a flagship initiative of the research group at the Douglas Mental Health University Institute and is closely affiliated with the Ludmer Centre for Neuroinformatics and Mental Health.

Overview

The core mission is to enable the development of preventive therapies by deeply characterizing the pre-symptomatic phase of Alzheimer's disease. It operates as both an observational study, tracking natural history, and a platform for interventional clinical trials. The study is distinguished by its focus on cognitively normal older adults who carry specific genetic risk factors, primarily the APOE-ε4 allele. Research activities are centralized at the Translational Neuroimaging Laboratory at the McGill University Research Centre for Studies in Aging, utilizing advanced techniques like amyloid PET, tau PET, and cerebrospinal fluid analysis.

Study Design and Objectives

The design integrates deep phenotyping with a readiness for interventional trials, following a cohort of asymptomatic at-risk individuals over many years. Primary objectives include defining the sequence of pathophysiological events in pre-clinical Alzheimer's disease, identifying sensitive biomarkers for early detection, and establishing a well-characterized cohort for testing preventive therapies. The study employs a multi-modal assessment protocol including magnetic resonance imaging, positron emission tomography, neuropsychological testing, and collection of blood and cerebrospinal fluid biomarkers. This data feeds into large-scale initiatives like the Alzheimer's Disease Neuroimaging Initiative for broader validation.

Participant Cohort

Participants are English- or French-speaking, cognitively normal individuals aged 55 to 85 with a confirmed family history of Alzheimer's disease in at least one first-degree relative. A key inclusion criterion is genetic predisposition, with many participants carrying one or two copies of the APOE-ε4 allele. The cohort is extensively characterized at baseline and undergoes annual follow-up assessments, creating a rich dataset of biological and cognitive trajectories. Recruitment and operations are managed through the Douglas Mental Health University Institute with ethical oversight from the McGill University Health Centre research ethics board.

Key Findings and Research Output

Research has contributed significantly to understanding the early neurobiology of Alzheimer's disease, particularly in mapping the accumulation of amyloid-beta and tau protein in asymptomatic brains. Studies have explored the relationships between genetics, brain structure, cognitive reserve, and biomarker profiles. The project has generated a vast, open-access data repository, shared with the global research community through platforms like the Global Alzheimer's Association Interactive Network. Output includes numerous publications in journals such as JAMA Neurology and Brain, advancing knowledge on pre-symptomatic disease staging.

Impact and Future Directions

The study has established a critical infrastructure for conducting prevention trials in Canada and has influenced the design of international studies like the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study. Its future directions include leveraging artificial intelligence and machine learning for predictive modeling, expanding biomarker discovery, and transitioning more candidates from observational tracking into novel interventional trials. The ultimate goal is to contribute to a paradigm shift from treating dementia to preventing it, influencing future guidelines from organizations like the Alzheimer's Association and World Health Organization.

Category:Alzheimer's disease research Category:Medical research studies Category:McGill University